Reviva Narrows Losses, Boosts Cash Amidst Ongoing Funding Needs

Ticker: RVPH · Form: 10-Q · Filed: Nov 13, 2025

Sentiment: mixed

Topics: Biotechnology, Pharmaceuticals, Clinical Stage, Going Concern, Equity Financing, Net Loss, R&D Expenses

TL;DR

**RVPH is burning less cash and raised capital, but they're still a going concern and need more money by Q2 2026, so expect more dilution.**

AI Summary

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) reported a net loss of $4.01 million for the three months ended September 30, 2025, a significant improvement from the $8.37 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $16.50 million, down from $23.66 million in the prior year. Research and development expenses decreased substantially, falling from $6.86 million in Q3 2024 to $2.13 million in Q3 2025, and from $18.23 million to $9.97 million for the nine-month periods. General and administrative expenses saw a slight increase to $1.90 million in Q3 2025 from $1.60 million in Q3 2024. The company's cash and cash equivalents stood at $13.18 million as of September 30, 2025, a slight decrease from $13.48 million at December 31, 2024. RVPH raised significant capital through financing activities, including $17.42 million from public offerings and $1.30 million from an At-The-Market (ATM) offering during the nine months ended September 30, 2025. Despite these capital raises, the company faces a going concern risk, as its current cash is only sufficient into the second quarter of 2026, necessitating further fundraising.

Why It Matters

For investors, RVPH's reduced net loss and successful capital raises, totaling over $18 million in the first nine months of 2025, indicate a more stable financial footing compared to the previous year. However, the explicit 'going concern' warning and the need for additional funding by Q2 2026 highlight significant future dilution risk. Employees might see continued job security in the short term due to the capital infusion, but long-term stability hinges on successful clinical trials and further financing. Customers and the broader market are less directly impacted by these financial results, but the company's ability to continue developing therapies for CNS, inflammatory, and cardiometabolic diseases depends entirely on its financial viability and successful drug development, placing it in a highly competitive pharmaceutical landscape.

Risk Assessment

Risk Level: high — The company explicitly states, "The Company's current cash on hand is not sufficient to satisfy its operating cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q" and "These conditions raise substantial doubt regarding the Company's ability to continue as a going concern for a period of one year after the date the financial statements are issued." This direct disclosure, coupled with an accumulated deficit of $180.8 million as of September 30, 2025, indicates a high financial risk.

Analyst Insight

Investors should exercise extreme caution and consider the high risk of further dilution. Monitor upcoming financing announcements closely and evaluate the progress of their clinical trials, as successful drug development is critical for long-term viability and reducing reliance on equity financing.

Financial Highlights

debt To Equity: 2.15
revenue: N/A
operating Margin: N/A
total Assets: $14.33M
total Debt: $0.00
net Income: -$4.01M
eps: -$0.06
gross Margin: N/A
cash Position: $13.18M
revenue Growth: N/A

Key Numbers

$4.01M — Net Loss (Q3 2025) (Decreased from $8.37M in Q3 2024, indicating improved operational efficiency.)
$16.50M — Net Loss (9M 2025) (Decreased from $23.66M in 9M 2024, showing a reduced burn rate year-over-year.)
$2.13M — R&D Expenses (Q3 2025) (Significantly down from $6.86M in Q3 2024, reflecting a shift in development pace or focus.)
$9.97M — R&D Expenses (9M 2025) (Reduced from $18.23M in 9M 2024, contributing to the overall lower net loss.)
$13.18M — Cash and Cash Equivalents (As of September 30, 2025, providing liquidity into Q2 2026.)
$18.79M — Net Cash Used in Operating Activities (9M 2025) (Lower than $24.44M in 9M 2024, indicating a more controlled cash burn.)
$18.50M — Net Cash Provided by Financing Activities (9M 2025) (Substantially increased from $6.63M in 9M 2024, reflecting successful capital raises.)
$180.8M — Accumulated Deficit (As of September 30, 2025, highlighting the company's history of losses.)
115,058,619 — Outstanding Common Shares (As of November 11, 2025, indicating significant share issuance and potential dilution.)
$3.8M — Working Capital Surplus (As of September 30, 2025, an improvement in short-term liquidity.)

Key Players & Entities

REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — registrant
Nasdaq Capital Market (regulator) — exchange where RVPH is listed
Securities and Exchange Commission (regulator) — filing authority
$4.01 million (dollar_amount) — net loss for three months ended September 30, 2025
$8.37 million (dollar_amount) — net loss for three months ended September 30, 2024
$16.50 million (dollar_amount) — net loss for nine months ended September 30, 2025
$23.66 million (dollar_amount) — net loss for nine months ended September 30, 2024
$13.18 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
$180.8 million (dollar_amount) — accumulated deficit as of September 30, 2025
Q2 2026 (date) — estimated period for cash sufficiency

FAQ

What were Reviva Pharmaceuticals Holdings, Inc.'s net losses for the three and nine months ended September 30, 2025?

Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $4,010,773 for the three months ended September 30, 2025, and a net loss of $16,497,223 for the nine months ended September 30, 2025.

How much cash and cash equivalents did RVPH have as of September 30, 2025?

As of September 30, 2025, RVPH had cash and cash equivalents totaling $13,183,259.

Did Reviva Pharmaceuticals Holdings, Inc. raise capital during the nine months ended September 30, 2025?

Yes, Reviva Pharmaceuticals Holdings, Inc. raised $17,419,703 from public offerings and $1,300,686 from an At-The-Market (ATM) offering, net of transaction costs, during the nine months ended September 30, 2025.

What is the primary risk identified in Reviva Pharmaceuticals Holdings, Inc.'s 10-Q filing?

The primary risk identified is a 'going concern' issue, as the company's current cash on hand is not sufficient to satisfy its operating cash needs for the next 12 months, and it will need additional fundraising by the second quarter of 2026.

How did research and development expenses change for RVPH in Q3 2025 compared to Q3 2024?

Research and development expenses for RVPH decreased significantly, from $6,858,285 for the three months ended September 30, 2024, to $2,131,444 for the three months ended September 30, 2025.

What was Reviva Pharmaceuticals Holdings, Inc.'s accumulated deficit as of September 30, 2025?

As of September 30, 2025, Reviva Pharmaceuticals Holdings, Inc. had an accumulated deficit of $180,770,273.

What is Reviva Pharmaceuticals Holdings, Inc.'s business focus?

Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing new therapies to address unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases.

How many shares of common stock were outstanding for RVPH as of November 11, 2025?

As of November 11, 2025, the number of outstanding shares of Reviva Pharmaceuticals Holdings, Inc.'s common stock was 115,058,619.

What was the net cash used in operating activities for RVPH during the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Reviva Pharmaceuticals Holdings, Inc. used $18,796,432 in net cash from operating activities.

What is the estimated timeframe for RVPH's current cash to cover anticipated outlays?

Reviva Pharmaceuticals Holdings, Inc. estimates that its current cash on hand is adequate to cover anticipated outlays into the second quarter of 2026.

Risk Factors

Going Concern Risk [high — financial]: The company's cash and cash equivalents of $13.18 million as of September 30, 2025, are projected to be sufficient only into the second quarter of 2026. This necessitates further fundraising to continue operations, highlighting a significant risk of insolvency if capital cannot be secured.
Dependence on Future Funding [high — operational]: RVPH has a history of net losses, with an accumulated deficit of $180.8 million as of September 30, 2025. The company's ability to continue as a going concern is heavily dependent on its success in raising additional capital through equity offerings or other financing activities.
Significant Reduction in R&D Spending [medium — operational]: Research and development expenses decreased substantially from $6.86 million in Q3 2024 to $2.13 million in Q3 2025, and from $18.23 million to $9.97 million for the nine-month periods. While this reduces burn rate, it could impact the pace of drug development and future product pipeline.
Accumulated Deficit [medium — financial]: The company has accumulated a deficit of $180.77 million as of September 30, 2025. This indicates a long-standing history of unprofitability, which could deter potential investors and lenders.
Dilution from Share Issuances [medium — financial]: The number of outstanding common shares increased significantly from 46,579,199 at December 31, 2024, to 96,337,119 as of September 30, 2025. This substantial increase, driven by capital raises, can lead to significant dilution for existing shareholders.

Industry Context

Reviva Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical industry. Success is driven by innovation, successful clinical trials, and regulatory approvals. The industry faces significant R&D costs and long development timelines, with many companies relying on external financing to fund operations.

Regulatory Implications

As a pharmaceutical company, RVPH is subject to stringent regulations from bodies like the FDA. Delays or failures in clinical trials, or issues with manufacturing and marketing, can lead to significant financial setbacks and regulatory hurdles. Compliance with evolving healthcare regulations is also critical.

What Investors Should Do

Monitor cash burn and future fundraising efforts.
Evaluate the impact of reduced R&D spending.
Assess the potential for shareholder dilution.

Key Dates

2025-09-30: End of Q3 2025 — Reported net loss of $4.01 million, improved R&D spending of $2.13 million, and cash reserves of $13.18 million.
2025-12-31: End of Fiscal Year 2024 — Reported cash and cash equivalents of $13.48 million and total assets of $15.50 million.
2024-09-30: End of Q3 2024 — Reported net loss of $8.37 million and R&D expenses of $6.86 million.

Glossary

Accumulated deficit: The total net losses of a company since its inception, minus any net profits. It represents the cumulative losses that have not been offset by profits. (Indicates the company's historical unprofitability, with RVPH having an accumulated deficit of $180.77 million as of September 30, 2025.)
Going concern: An accounting assumption that a business will continue to operate for the foreseeable future. If there are substantial doubts about this, it must be disclosed. (RVPH faces a going concern risk as its current cash is only sufficient into Q2 2026, requiring further fundraising.)
At-The-Market (ATM) offering: A type of public offering where a company sells its shares directly into the open market over a period of time, typically at prevailing market prices. (RVPH raised $1.30 million through an ATM offering during the nine months ended September 30, 2025, as part of its capital-raising strategy.)
Warrant liabilities: Liabilities arising from warrants (options to purchase stock) that are accounted for separately from equity, often due to specific terms or marketability. (RVPH had warrant liabilities of $44,506 as of September 30, 2025, which decreased from $89,010 at the end of 2024.)
Additional paid-in capital: The amount of capital that shareholders have paid to the company for stock above its par value. (Represents a significant portion of RVPH's equity, totaling $185.31 million as of September 30, 2025, reflecting capital raised from stock issuances.)

Year-Over-Year Comparison

Compared to the prior year, Reviva Pharmaceuticals has significantly reduced its net loss, from $8.37 million in Q3 2024 to $4.01 million in Q3 2025, and from $23.66 million to $16.50 million for the nine-month periods. This improvement is largely driven by a substantial decrease in R&D expenses, falling from $6.86 million to $2.13 million in Q3 and $18.23 million to $9.97 million year-to-date. While operating expenses have decreased, the company's cash position has slightly declined, and it continues to face a going concern risk due to its limited cash runway.

Filing Stats: 4,321 words · 17 min read · ~14 pages · Grade level 15.7 · Accepted 2025-11-13 16:11:41

Key Financial Figures

$0.0001 — ch registered Common Stock, par value $0.0001 per share RVPH The Nasdaq Capital M

Filing Documents

rvph20250930_10q.htm (10-Q) — 1297KB
ex_880405.htm (EX-31.1) — 9KB
ex_880406.htm (EX-31.2) — 9KB
ex_880407.htm (EX-32.1) — 7KB
g01.jpg (GRAPHIC) — 73KB
graph01.jpg (GRAPHIC) — 39KB
graph02.jpg (GRAPHIC) — 43KB
0001437749-25-034827.txt ( ) — 6563KB
rvph-20250930.xsd (EX-101.SCH) — 54KB
rvph-20250930_def.xml (EX-101.DEF) — 364KB
rvph-20250930_lab.xml (EX-101.LAB) — 290KB
rvph-20250930_pre.xml (EX-101.PRE) — 392KB
rvph-20250930_cal.xml (EX-101.CAL) — 24KB
rvph20250930_10q_htm.xml (XML) — 1072KB

Financial Statements (unaudited)

Financial Statements (unaudited) F-1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 F-1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 F-2 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 F-3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 F-5 Notes to Condensed Consolidated Financial Statements F-6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 1 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 17 Item 4.

Controls and Procedures

Controls and Procedures 17 Part II Other Information 19 Item 1.

Legal Proceedings

Legal Proceedings 19 Item 1A.

Risk Factors

Risk Factors 19 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3. Defaults Upon Senior Securities 20 Item 4. Mine Safety Disclosures 20 Item 5. Other Information 20 Item 6. Exhibits 21

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) September 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 13,183,259 $ 13,476,331 Prepaid clinical trial costs 81,742 540,601 Prepaid expenses and other current assets 247,927 666,435 Total current assets 13,512,928 14,683,367 Non-current prepaid clinical trial costs 819,721 819,721 Total Assets $ 14,332,649 $ 15,503,088 Liabilities and Stockholders ' Equity Liabilities Short-term debt $ — $ 458,154 Accounts payable 5,431,806 6,283,430 Accrued clinical expenses 2,891,175 6,723,719 Accrued compensation 784,956 635,587 Other accrued liabilities 630,471 500,616 Total current liabilities 9,738,408 14,601,506 Warrant liabilities 44,506 89,010 Total Liabilities 9,782,914 14,690,516 Commitments and contingencies (Note 6) Stockholders' Equity Common stock, par value of $ 0.0001 ; 315,000,000 shares authorized; 96,337,119 and 46,579,199 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 9,618 4,658 Preferred Stock, par value of $ 0.0001 ; 10,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Additional paid-in capital 185,310,390 165,080,964 Accumulated deficit ( 180,770,273 ) ( 164,273,050 ) Total stockholders' equity 4,549,735 812,572 Total Liabilities and Stockholders ' Equity $ 14,332,649 $ 15,503,088 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. F-1 REVIVA PHARMACEUTICALS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Operating expenses Research and development $ 2,131,444 $ 6,858,285 $ 9,969,736